Hospital & Healthcare Services · Founded 2008 · www.tejnaksh.com · BSE 539428 · · ISIN INE030T01027
No Notes Added Yet
Business
Tejnaksh Healthcare Ltd. is an India-based company operating in the Hospital & Healthcare Services sector. Its core business model involves providing a range of medical and healthcare services through its healthcare facilities. The company primarily generates revenue by offering inpatient and outpatient care, diagnostic services, surgical procedures, and other specialized medical treatments to patients. This includes revenue from consultation fees, treatment packages, facility charges, and potentially pharmacy sales within its premises.
Revenue Mix
Specific breakdown of revenue by key segments (e.g., inpatient vs. outpatient, diagnostics, specific specialties) is not publicly available in the provided information. However, typical revenue streams for a hospital and healthcare service provider like Tejnaksh would primarily stem from patient services, including general medical consultations, specialized treatments, surgical interventions, intensive care, laboratory tests, imaging services, and pharmacy sales.
Industry
The Indian Hospital & Healthcare Services industry is large, diverse, and experiencing significant growth, driven by increasing healthcare awareness, rising disposable incomes, and a growing incidence of chronic and lifestyle diseases. The industry is characterized by a mix of large corporate hospital chains, regional multi-specialty hospitals, and smaller single-specialty clinics. Tejnaksh Healthcare operates within this competitive landscape. Without specific market share data or details of its operational scale, its positioning is likely as a regional or mid-sized player, potentially focusing on specific geographies or niche services, competing with both larger established chains and other independent hospitals.
MOAT
For a company of this nature, a strong competitive advantage (moat) can be challenging to establish without significant scale, unique specialization, or deep local entrenchment. Tejnaksh Healthcare may possess localized advantages such as strong brand recognition within its operational footprint, established relationships with local medical practitioners, patient loyalty built on trust and quality of service, or strategic geographical placement. However, it is unlikely to have a wide, durable moat based purely on scale or network effects typical of larger players, or high switching costs in a highly competitive market.
Growth Drivers
Key factors that can drive Tejnaksh Healthcare's growth over the next 3-5 years include:
Growing Demand: India's increasing population, rising middle class, and higher health expenditure per capita will continue to fuel demand for healthcare services.
Lifestyle Diseases: The rising prevalence of chronic and lifestyle-related diseases creates a sustained demand for specialized medical care.
Government Initiatives: Schemes like Ayushman Bharat (Pradhan Mantri Jan Arogya Yojana) can increase access to healthcare and patient volumes for empanelled hospitals.
Service Expansion: Introducing new specialties, advanced medical procedures, or diagnostic capabilities to attract a wider patient base.
Geographic Expansion: Opening new facilities or expanding capacity in underserved or high-growth regions.
Risks
Intense Competition: The Indian healthcare market is highly competitive, potentially leading to pricing pressures and challenges in attracting and retaining patients and medical talent.
Regulatory Changes: Changes in healthcare policies, pricing regulations (e.g., caps on medical device costs or procedure charges), and quality standards can impact profitability and operational costs.
Talent Retention: Shortage of skilled doctors, nurses, and paramedical staff, coupled with high attrition rates, can lead to increased wage costs and impact service quality.
Capital Intensive Nature: Operating hospitals requires significant capital expenditure for infrastructure, medical equipment, and technology upgrades, potentially leading to debt accumulation.
Medical Malpractice & Reputation Risk: Incidents of medical errors or service quality issues can severely damage reputation and lead to legal liabilities.
Economic Downturns: Reduced discretionary spending by patients or delays in elective procedures during economic slowdowns can affect patient volumes and revenue.
Management & Ownership
In many Indian companies, promoters (founding families or individuals) typically hold significant ownership stakes and play a crucial role in management and strategic direction. Without specific details on Tejnaksh Healthcare Ltd.'s management team's background, experience, or corporate governance practices, a definitive assessment of management quality is not possible. However, promoter-led management often brings long-term vision but can also concentrate decision-making power. The ownership structure likely involves a substantial promoter holding, common among Indian listed entities.
Outlook
Tejnaksh Healthcare operates in a fundamentally strong growth industry driven by long-term demographic and economic tailwinds in India. The increasing demand for quality healthcare services presents significant opportunities for expansion and revenue growth. However, the company faces considerable challenges from intense competition, the capital-intensive nature of the business, and evolving regulatory frameworks. Its ability to carve out a distinct competitive position, maintain high standards of patient care, effectively manage operational costs, and strategically expand its services and footprint will be crucial for sustained success. The outlook is cautiously optimistic, balancing the sector's robust growth potential against significant operational and competitive hurdles.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Total Expenditure | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 2 |
| Operating Profit | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adjustments | 0 | -0 | -0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 |
| Profit After Adjustments | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Adjusted Earnings Per Share | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.1 | 0.2 | 0.2 | 0.2 | 0.1 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 5 | 7 | 14 | 20 | 17 | 12 | 13 | 12 | 12 | 13 | 12 |
| Other Income | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 5 | 7 | 15 | 21 | 17 | 12 | 13 | 12 | 12 | 13 | 12 |
| Total Expenditure | 2 | 4 | 9 | 16 | 13 | 8 | 8 | 8 | 9 | 9 | 8 |
| Operating Profit | 2 | 3 | 6 | 6 | 4 | 4 | 5 | 4 | 4 | 5 | 4 |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 2 | 3 | 4 | 4 | 3 | 3 | 4 | 3 | 2 | 3 | 1 |
| Provision for Tax | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Profit After Tax | 1 | 2 | 3 | 3 | 2 | 2 | 3 | 2 | 2 | 2 | 0 |
| Adjustments | 0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | 0 | 0 |
| Profit After Adjustments | 1 | 2 | 3 | 3 | 2 | 2 | 3 | 2 | 2 | 2 | 0 |
| Adjusted Earnings Per Share | 0.7 | 0.9 | 1.4 | 1.5 | 1 | 1 | 1.3 | 0.8 | 0.9 | 1.1 | 0.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 8% | 0% | -5% | 0% |
| Operating Profit CAGR | 25% | 0% | 5% | 0% |
| PAT CAGR | 0% | -13% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -27% | -26% | -22% | 2% |
| ROE Average | 9% | 8% | 11% | 18% |
| ROCE Average | 13% | 12% | 13% | 21% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 6 | 8 | 10 | 13 | 15 | 17 | 20 | 22 | 24 | 26 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Borrowings | 0 | 6 | 6 | 6 | 7 | 4 | 6 | 6 | 4 | 1 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Total Current Liabilities | 0 | 1 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 1 |
| Total Liabilities | 7 | 16 | 20 | 22 | 25 | 25 | 30 | 31 | 31 | 30 |
| Fixed Assets | 3 | 14 | 15 | 17 | 17 | 15 | 15 | 23 | 23 | 21 |
| Other Non-Current Assets | 3 | 0 | 1 | 1 | 1 | 6 | 9 | 2 | 2 | 3 |
| Total Current Assets | 1 | 2 | 3 | 5 | 7 | 3 | 5 | 6 | 6 | 6 |
| Total Assets | 7 | 16 | 20 | 22 | 25 | 25 | 30 | 31 | 31 | 30 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 2 |
| Cash Flow from Operating Activities | 4 | 2 | 4 | 3 | 1 | 1 | 9 | 2 | 4 | 0 |
| Cash Flow from Investing Activities | -3 | -8 | -3 | -2 | -1 | 2 | -11 | -1 | -1 | 4 |
| Cash Flow from Financing Activities | -0 | 6 | -1 | -2 | 0 | -3 | 2 | -1 | -2 | -4 |
| Net Cash Inflow / Outflow | 0 | 1 | 1 | -0 | 0 | -0 | 0 | -0 | 1 | 0 |
| Closing Cash & Cash Equivalent | 0 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.65 | 0.9 | 1.41 | 1.49 | 1.03 | 1.01 | 1.34 | 0.83 | 0.87 | 1.15 |
| CEPS(Rs) | 0.75 | 1.11 | 1.8 | 1.83 | 1.38 | 1.35 | 1.71 | 1.31 | 1.31 | 1.55 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 3.07 | 3.97 | 4.99 | 6.48 | 7.51 | 8.52 | 9.87 | 10.72 | 11.6 | 12.76 |
| Core EBITDA Margin(%) | 48.26 | 43.84 | 37.75 | 21.16 | 23.6 | 31.04 | 37.56 | 31.57 | 29.89 | 31.8 |
| EBIT Margin(%) | 44.71 | 41.7 | 37.22 | 26.02 | 21.77 | 26.51 | 33.46 | 26.74 | 24.97 | 27.88 |
| Pre Tax Margin(%) | 44.66 | 39.02 | 30.28 | 22.09 | 17.33 | 22.31 | 29.67 | 21.43 | 19.51 | 24.75 |
| PAT Margin (%) | 27.84 | 26.2 | 22.51 | 15.88 | 12.54 | 17.3 | 22.18 | 15.28 | 14.49 | 17.29 |
| Cash Profit Margin (%) | 32.18 | 30.98 | 25.81 | 18.85 | 16.36 | 22.99 | 27.43 | 22.73 | 21.93 | 24.35 |
| ROA(%) | 19.32 | 16.96 | 17.97 | 14.93 | 9.1 | 8.36 | 10.38 | 5.89 | 5.64 | 7.23 |
| ROE(%) | 21.17 | 26.68 | 34.98 | 26.93 | 15.1 | 12.71 | 15.05 | 8.57 | 7.78 | 9.02 |
| ROCE(%) | 34 | 29.35 | 32.66 | 27.59 | 17.78 | 14.2 | 17.22 | 11.36 | 10.76 | 13 |
| Receivable days | 0 | 0 | -0.79 | 1.48 | 7.64 | 15.14 | 14.86 | 33.36 | 31.48 | 33.57 |
| Inventory Days | 13.63 | 11.91 | 13.12 | 14.35 | 15.67 | 20.33 | 20.42 | 21.59 | 22.11 | 22.63 |
| Payable days | 115.23 | 158.84 | 192.56 | 204.37 | 160.23 | 205.86 | 110.16 | 120.22 | 110 | 73.7 |
| PER(x) | 6.85 | 44.1 | 32.72 | 18.67 | 17.49 | 36.02 | 62.83 | 41.59 | 26.49 | 18.31 |
| Price/Book(x) | 1.45 | 9.97 | 9.26 | 4.29 | 2.4 | 4.27 | 8.53 | 3.22 | 2 | 1.64 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 1.8 | 11.76 | 7.06 | 3.12 | 2.48 | 6.49 | 13.82 | 6.25 | 3.91 | 3.25 |
| EV/Core EBITDA(x) | 3.68 | 25.3 | 17.41 | 10.74 | 9.69 | 20.15 | 35.69 | 18.27 | 12.06 | 9.3 |
| Net Sales Growth(%) | 0 | 53.42 | 94.16 | 39.76 | -13.37 | -30.13 | 5.99 | -7.49 | 3.82 | 5.93 |
| EBIT Growth(%) | 0 | 43.09 | 73.32 | -2.3 | -27.52 | -14.93 | 33.79 | -26.07 | -3.06 | 18.29 |
| PAT Growth(%) | 0 | 44.39 | 66.82 | -1.45 | -31.59 | -3.56 | 35.87 | -36.28 | -1.54 | 26.45 |
| EPS Growth(%) | 0 | 37.93 | 57.36 | 5.49 | -30.92 | -1.77 | 32.68 | -38.22 | 5.54 | 31.06 |
| Debt/Equity(x) | 0 | 0.79 | 0.75 | 0.48 | 0.47 | 0.28 | 0.35 | 0.29 | 0.2 | 0.04 |
| Current Ratio(x) | 2.07 | 2.54 | 1.03 | 1.99 | 3.77 | 1.89 | 2.94 | 3.82 | 3.86 | 5.29 |
| Quick Ratio(x) | 1.66 | 2.17 | 0.79 | 1.63 | 3.41 | 1.48 | 2.51 | 3.41 | 3.33 | 4.56 |
| Interest Cover(x) | 874.41 | 15.56 | 5.36 | 6.61 | 4.9 | 6.31 | 8.84 | 5.03 | 4.57 | 8.9 |
| Total Debt/Mcap(x) | 0 | 0.08 | 0.08 | 0.11 | 0.2 | 0.07 | 0.04 | 0.09 | 0.1 | 0.02 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 73.83 | 73.83 | 73.83 | 73.83 | 73.83 | 73.83 | 73.83 | 73.83 | 73.83 | 73.83 |
| FII | 0.28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 25.89 | 26.17 | 26.17 | 26.17 | 26.17 | 26.17 | 26.17 | 26.17 | 26.17 | 26.17 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 |
| FII | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.03 | 2.03 | 2.03 | 2.03 | 2.03 | 2.03 | 2.03 | 2.03 | 2.03 | 2.03 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +8% | 0% | -5% | — |
| Operating Profit CAGR | +25% | 0% | +5% | — |
| PAT CAGR | 0% | -13% | 0% | — |
| Share Price CAGR | -27% | -26% | -22% | +2% |
| ROE Average | +9% | +8% | +11% | +18% |
| ROCE Average | +13% | +12% | +13% | +21% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 73.83 | 73.83 | 73.83 | 73.83 | 73.83 | 73.83 | 73.83 | 73.83 | 73.83 | 73.83 |
| FII | 0.28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 25.89 | 26.17 | 26.17 | 26.17 | 26.17 | 26.17 | 26.17 | 26.17 | 26.17 | 26.17 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 |
| FII | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.03 | 2.03 | 2.03 | 2.03 | 2.03 | 2.03 | 2.03 | 2.03 | 2.03 | 2.03 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.